BeyondSpring (BYSI) was retreating by more than 51% after saying the US Food and Drug Administration rejected its new drug application seeking approval of plinabulin in combination with granulocyte to prevent chemotherapy-induced neutropenia.
BioXcel Therapeutics (BTAI) was down more than 17% after saying the FDA has extended the Prescription Drug User Fee Act date for its review of the new-drug application of BXCL501 to treat agitation associated with schizophrenia and bipolar disorder to April 5 from Jan. 5.
Bright Health Group's (BHG) NeueHealth unit said it plans to open at least 25 clinics in Florida, Texas, and North Carolina, taking its total to more than 70 owned clinics by early 2022. Bright Health Group was climbing past 2% in recent trading.
|Archer-Daniels-Midland, New Culture Team Up to Devel...|
|Stifel Lowers Rocket Lab USA's Price Target to $15 F...|
|Correction: Odeon Capital Downgrades Bed Bath & Beyo...|
|Enlivex Therapeutics Receives Israeli Health Ministr...|
|--Oppenheimer Adjusts QuickLogic's Price Target to $...|